Bacteremia Sepsis
10
1
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)
Initial Feasibility Study of the CycloPE® Device
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
Machine Learning Assisted Electrochemical Profiling to Provide Early Identification of Bloodstream Infections Pathogens
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis
Risk Factors of Post-ERCP Sepsis
Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia and Fungemia.
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
Prevalence and Characterization of Diagnostic Error Among Patients With Bacteremia